Αποτελέσματα Αναζήτησης
An ideal vaccine will prevent both genital lesions and asymptomatic subclinical infection to reduce the risk of inadvertent transmission to partners, will be effective against genital herpes caused by herpes simplex virus types 1 and 2 (HSV-1, HSV-2), and will protect against neonatal herpes.
Our results of immunotherapy with GEN-003, a novel vaccine for genital herpes, composed of HSV-2 gD2ΔTMR and a fragment of ICP4 protein (ICP4.2) adjuvanted with Matrix-M2, demonstrate that it had an acceptable safety profile, was immunogenic, and reduced both recurrent viral shedding and the number of days with lesions at doses of 30 µg and ...
1 Ιουν 2020 · An ideal vaccine will prevent both genital lesions and asymptomatic subclinical infection to reduce the risk of inadvertent transmission to partners, will be effective against genital herpes caused by herpes simplex virus types 1 and 2 (HSV-1, HSV-2), and will protect against neonatal herpes.
14 Μαΐ 2019 · Two sets of PPCs are described: PPCs for prophylactic HSV vaccines to be used primarily before exposure to HSV-2 to prevent infection. Prevention of HSV-2 infection would prevent associated GUD and HSV transmission, including to neonates as neonatal herpes, as well as HSV-2-associated HIV acquisition.
25 Ιουλ 2024 · Vaccination strategy: routine vaccination of male, female or both, symptomatic HSV-2 positive (25 % of those who acquire HSV-2). Scale-up at a constant rate to achieve 80 % coverage within 10 years.
8 Ιουλ 2022 · Double-blind, placebo-controlled trial of a herpes simplex virus type 2 glycoprotein vaccine in persons at high risk for genital herpes infection.
We also review what is known of the natural immune control of herpes lesions, via interacting innate immunity and CD4 and CD8 T cells and the lessons they provide for development of new, more effective vaccines.
